Top-News
Pharmazeutika USA

Merrimack Pharmaceuticals Inc News

Aktie
WKN:  A2DW3Q ISIN:  US5903282094 US-Symbol:  MACK
15,005 $
-0,015 $
-0,10%
03.05.24 21:58:00
Handeln Depot/Watchlist
Aktienanzahl *
14,32 Mio.
Marktkapitalisierung *
200,22 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 16.02.2024

Merrimack Pharmaceuticals Inc News

27.09.23 - PR Newswire
Mackmyra Identitet - a dynamic showdown
Mackmyra Identitet - a dynamic showdown PR Newswire
12.04.23 - PR Newswire
Exclusive small batch from Mackmyra - only 3017 bottles
Exclusive small batch from Mackmyra - only 3017 bottles PR Newswire
09.11.22 - PR Newswire
Thinking about buying stock in Merrimack Pharmaceuticals, Roblox, Mullen Automotive, Plug Power, or Yamana Gold?
Thinking about buying stock in Merrimack Pharmaceuticals, Roblox, Mullen Automotive, Plug Power, or Yamana Gold? PR Newswire
29.09.22 - PR Newswire
Mackmyra launches Extra Rök 2.0
Mackmyra launches Extra Rök 2.0 PR Newswire
21.09.22 - PR Newswire
Mackmyra launches Destination
Mackmyra launches Destination PR Newswire
18.05.22 - PR Newswire
Mackmyra presents the grand finale with Moment Virvelvind
Mackmyra presents the grand finale with Moment Virvelvind PR Newswire
02.03.22 - PR Newswire
Mackmyra launches luxury swedish whisky with a french connection
Mackmyra launches luxury swedish whisky with a french connection PR Newswire
10.11.21 - PR Newswire
Mackmyra launches peated deluxe version of a celebrated classic
Mackmyra launches peated deluxe version of a celebrated classic PR Newswire
24.09.19 - PR Newswire
JFL Capital Ends Campaign at Merrimack
JFL Capital Ends Campaign at Merrimack Pleased Involvement Catalyzed Much Needed Change at Merrimack and Intends to Continue to Monitor Situation PR Newswire
22.08.19 - PR Newswire
JFL Capital Issues Letter to Fellow Merrimack Stockholders
JFL Capital Issues Letter to Fellow Merrimack Stockholders Believes Significant Destruction of Value and Lack of Alignment with Stockholders Warrants an Overhaul in the ...
30.05.19 - PR Newswire
Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend PR Newswire
10.05.19 - PR Newswire
Merrimack Reports First Quarter 2019 Financial Results
Merrimack Reports First Quarter 2019 Financial Results PR Newswire
09.04.19 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK PR Newswire
09.04.19 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK PR Newswire
04.04.19 - PR Newswire
Merrimack Discontinues Development of MM-310
Merrimack Discontinues Development of MM-310 -- Safety update shows Phase 1 study unable to reach optimal therapeutic index for MM-310 due to continued observation of ...
06.03.19 - PR Newswire
Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
07.11.18 - PR Newswire
Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review - Company to initiate corporate restructuring, including ~60% ...
31.10.18 - PR Newswire
Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call
Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call PR Newswire
19.10.18 - PR Newswire
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility - MM-121 did not improve progression free survival (PFS) ...
20.09.18 - PR Newswire
Merrimack Receives $5 Million Milestone Payment from Shire
Merrimack Receives $5 Million Milestone Payment from Shire PR Newswire

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »